{"id":386630,"date":"2020-11-23T08:03:34","date_gmt":"2020-11-23T13:03:34","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=386630"},"modified":"2020-11-23T08:03:34","modified_gmt":"2020-11-23T13:03:34","slug":"laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\/","title":{"rendered":"Laidlaw Venture Partners Portfolio Company Voltron Therapeutics Enters into Strategic Development Agreement With Translational Drug Development (TD2), a Precision Oncology Contract Research Organization (CRO)"},"content":{"rendered":"

\nThe Companies Plan to Focus On Voltron\u2019s VaxCelerate Vaccine Platform\u2019s Effectiveness and Utility in a Variety of Tumor Settings
\n<\/h2>\n
\n

NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) — Laidlaw Venture Partners (\u201cLVP\u201d), the venture capital arm of\u00a0Laidlaw & Company (UK) Ltd., today announced a strategic development agreement with Translational Drug Development (TD2), a precision oncology contract research organization (CRO).<\/p>\n

Over time the two companies plan to focus on Voltron\u2019s VaxCelerate vaccine platform\u2019s effectiveness and utility in a variety of tumor settings. The mutual effort is designed to evaluate several development and regulatory strategies, including pre-clinical work, indication\/patient population selection, trial site selection and supporting Voltron\u2019s initial BLA submission.<\/p>\n

\u201cVoltron is excited to have forged a relationship with TD2 to best leverage and develop our novel vaccine platform, VaxCelerate. We believe TD2\u2019s wide ranging expertise in oncology, from trial design and execution to regulatory strategy across all cancer types, will help Voltron create differentiating data to bring more effective treatments to market in less time. Our highly experienced operations team was instrumental in the selection process and was extremely impressed with TD2\u2019s capabilities, track record and responsiveness. Our initial project will focus on VaxCelerate in the ovarian cancer setting with additional consideration being given to potential future opportunities in NSCLC, pancreatic cancer, head and neck cancer and mesothelioma,\u201d said Pat Gallagher, Managing Partner at LVP and CEO of Voltron.<\/p>\n

\u201cTD2 is honored to be selected to work with the great team at Voltron to accelerate this novel self-assembling vaccine medicine\u00a0to help patients with ovarian and other cancers,\u201d said Stephen Gately, CEO at TD2. \u201cWe look forward to deploying our full translational oncology service offerings to support all needed aspects of development with a key focus on the clinical and regulatory strategy to select patients most likely to gain clinical benefit.\u201d<\/p>\n

“It continues to be an exciting time of growth for Laidlaw Venture Partners, and in particular, our portfolio company Voltron Therapeutics. In past months, we have announced the addition of numerous world class healthcare professionals to our team. Today\u2019s Voltron news is a result of leveraging that team\u2019s experience, varied skill sets and invaluable relationships forged over decades of specialized work in the medical field,\u201d said James Ahern, Founding Partner, Laidlaw Venture Partners.<\/p>\n

\n About Laidlaw & Company<\/strong>\n <\/p>\n

Laidlaw & Company is a full-service investment banking and brokerage firm offering personalized investment advice and skillful execution to private institutions, public institutions, and high net worth individual investors.<\/p>\n

Laidlaw & Company (U.K.) Ltd., a broker-dealer registered with FINRA in\u00a0the United States, clears on a fully disclosed basis through INTL FC Stone Financial Inc., a member of the Securities Investor Protection Corporation (SIPC). Laidlaw & Company International Limited, an affiliate of Laidlaw & Company, is authorized by the Financial Conduct Authority (FCA) in the\u00a0United Kingdom.<\/p>\n

Laidlaw Wealth Management is an affiliate of, and Laidlaw Venture Partners is a DBA, of Laidlaw & Company. For more information, please visit:\u00a0https:\/\/laidlawltd.com\/<\/strong><\/a><\/p>\n

\n About Translational Drug Development (TD2)<\/strong>\n <\/p>\n

TD2 is an oncology development company that provides innovative services for oncology-focused organizations. Using a dedicated team of professionals with broad experience and understanding in oncology drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncologic diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, and clinical trial design and execution. TD2\u2019s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new medicine, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit\u00a0www.TD2inc.com<\/u><\/a>.<\/p>\n

\n Investor Contacts:<\/strong>\n <\/p>\n

Matt Duffy, Managing Partner
646-335-5923
mduffy@laidlawltd.com<\/a>\u00a0<\/strong><\/p>\n

Jason Assad
Investor Relations
678-570-6791
jwassad@bellsouth.net<\/a><\/u><\/strong><\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

The Companies Plan to Focus On Voltron\u2019s VaxCelerate Vaccine Platform\u2019s Effectiveness and Utility in a Variety of Tumor Settings NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) — Laidlaw Venture Partners (\u201cLVP\u201d), the venture capital arm of\u00a0Laidlaw & Company (UK) Ltd., today announced a strategic development agreement with Translational Drug Development (TD2), a precision oncology contract research organization (CRO). Over time the two companies plan to focus on Voltron\u2019s VaxCelerate vaccine platform\u2019s effectiveness and utility in a variety of tumor settings. The mutual effort is designed to evaluate several development and regulatory strategies, including pre-clinical work, indication\/patient population selection, trial site selection and supporting Voltron\u2019s initial BLA submission. \u201cVoltron is excited to have forged a relationship with TD2 to best leverage … <\/p>\n

Continue reading “Laidlaw Venture Partners Portfolio Company Voltron Therapeutics Enters into Strategic Development Agreement With Translational Drug Development (TD2), a Precision Oncology Contract Research Organization (CRO)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-386630","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLaidlaw Venture Partners Portfolio Company Voltron Therapeutics Enters into Strategic Development Agreement With Translational Drug Development (TD2), a Precision Oncology Contract Research Organization (CRO) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Laidlaw Venture Partners Portfolio Company Voltron Therapeutics Enters into Strategic Development Agreement With Translational Drug Development (TD2), a Precision Oncology Contract Research Organization (CRO) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"The Companies Plan to Focus On Voltron\u2019s VaxCelerate Vaccine Platform\u2019s Effectiveness and Utility in a Variety of Tumor Settings NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) — Laidlaw Venture Partners (\u201cLVP\u201d), the venture capital arm of\u00a0Laidlaw & Company (UK) Ltd., today announced a strategic development agreement with Translational Drug Development (TD2), a precision oncology contract research organization (CRO). Over time the two companies plan to focus on Voltron\u2019s VaxCelerate vaccine platform\u2019s effectiveness and utility in a variety of tumor settings. The mutual effort is designed to evaluate several development and regulatory strategies, including pre-clinical work, indication\/patient population selection, trial site selection and supporting Voltron\u2019s initial BLA submission. \u201cVoltron is excited to have forged a relationship with TD2 to best leverage … Continue reading "Laidlaw Venture Partners Portfolio Company Voltron Therapeutics Enters into Strategic Development Agreement With Translational Drug Development (TD2), a Precision Oncology Contract Research Organization (CRO)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-23T13:03:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDI3MSMzODM4NzE4IzIyMDA0NzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Laidlaw Venture Partners Portfolio Company Voltron Therapeutics Enters into Strategic Development Agreement With Translational Drug Development (TD2), a Precision Oncology Contract Research Organization (CRO)\",\"datePublished\":\"2020-11-23T13:03:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\\\/\"},\"wordCount\":673,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDI3MSMzODM4NzE4IzIyMDA0NzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\\\/\",\"name\":\"Laidlaw Venture Partners Portfolio Company Voltron Therapeutics Enters into Strategic Development Agreement With Translational Drug Development (TD2), a Precision Oncology Contract Research Organization (CRO) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDI3MSMzODM4NzE4IzIyMDA0NzI=\",\"datePublished\":\"2020-11-23T13:03:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDI3MSMzODM4NzE4IzIyMDA0NzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDI3MSMzODM4NzE4IzIyMDA0NzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Laidlaw Venture Partners Portfolio Company Voltron Therapeutics Enters into Strategic Development Agreement With Translational Drug Development (TD2), a Precision Oncology Contract Research Organization (CRO)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Laidlaw Venture Partners Portfolio Company Voltron Therapeutics Enters into Strategic Development Agreement With Translational Drug Development (TD2), a Precision Oncology Contract Research Organization (CRO) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\/","og_locale":"en_US","og_type":"article","og_title":"Laidlaw Venture Partners Portfolio Company Voltron Therapeutics Enters into Strategic Development Agreement With Translational Drug Development (TD2), a Precision Oncology Contract Research Organization (CRO) - Market Newsdesk","og_description":"The Companies Plan to Focus On Voltron\u2019s VaxCelerate Vaccine Platform\u2019s Effectiveness and Utility in a Variety of Tumor Settings NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) — Laidlaw Venture Partners (\u201cLVP\u201d), the venture capital arm of\u00a0Laidlaw & Company (UK) Ltd., today announced a strategic development agreement with Translational Drug Development (TD2), a precision oncology contract research organization (CRO). Over time the two companies plan to focus on Voltron\u2019s VaxCelerate vaccine platform\u2019s effectiveness and utility in a variety of tumor settings. The mutual effort is designed to evaluate several development and regulatory strategies, including pre-clinical work, indication\/patient population selection, trial site selection and supporting Voltron\u2019s initial BLA submission. \u201cVoltron is excited to have forged a relationship with TD2 to best leverage … Continue reading \"Laidlaw Venture Partners Portfolio Company Voltron Therapeutics Enters into Strategic Development Agreement With Translational Drug Development (TD2), a Precision Oncology Contract Research Organization (CRO)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-23T13:03:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDI3MSMzODM4NzE4IzIyMDA0NzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Laidlaw Venture Partners Portfolio Company Voltron Therapeutics Enters into Strategic Development Agreement With Translational Drug Development (TD2), a Precision Oncology Contract Research Organization (CRO)","datePublished":"2020-11-23T13:03:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\/"},"wordCount":673,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDI3MSMzODM4NzE4IzIyMDA0NzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\/","name":"Laidlaw Venture Partners Portfolio Company Voltron Therapeutics Enters into Strategic Development Agreement With Translational Drug Development (TD2), a Precision Oncology Contract Research Organization (CRO) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDI3MSMzODM4NzE4IzIyMDA0NzI=","datePublished":"2020-11-23T13:03:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDI3MSMzODM4NzE4IzIyMDA0NzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDI3MSMzODM4NzE4IzIyMDA0NzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/laidlaw-venture-partners-portfolio-company-voltron-therapeutics-enters-into-strategic-development-agreement-with-translational-drug-development-td2-a-precision-oncology-contract-research-organizati\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Laidlaw Venture Partners Portfolio Company Voltron Therapeutics Enters into Strategic Development Agreement With Translational Drug Development (TD2), a Precision Oncology Contract Research Organization (CRO)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/386630","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=386630"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/386630\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=386630"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=386630"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=386630"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}